Activation of the prolactin receptor (PrlR) and JAK2-STAT3 signaling pathway persists in ERα+/PR+ breast tumors to provide a critical survival signal during tumor recurrence [16–19]. This evidence concerns the gene JAK2 and breast neoplasm.